{"filing":{"accession_number":"0001104659-26-094869","cik":"0001868279","ticker":"AVBP","company_name":"ArriVent BioPharma, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-11","primary_document":"tm2622880d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926094869/tm2622880d1_8k.htm"},"events":[{"id":27177,"run_id":24752,"accession_number":"0001104659-26-094869","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"ArriVent entered into an exclusive, sublicensable license agreement with Shanghai Allist Pharmaceuticals on August 11, 2026, granting Allist rights to develop and commercialize ARR-002 in Greater China, with up to $80.6 million in potential payments and a joint global development collaboration committee.","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28598,"accession_number":"0001104659-26-094869","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"ArriVent entered into an exclusive, sublicensable license agreement with Shanghai Allist Pharmaceuticals on August 11, 2026, granting Allist rights to develop and commercialize ARR-002 in Greater China. The agreement provides for up to $80.6 million in potential payments (upfront, milestones, and royalties), establishes a collaboration committee for joint global development, and represents a material strategic transaction affecting the company's development and commercialization rights for a key asset. This constitutes a material definitive agreement under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:16.782715+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":27178,"run_id":24752,"accession_number":"0001104659-26-094869","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ArriVent disclosed Q2 2026 financial results (ended June 30, 2026) via press release on August 12, 2026, reporting a net loss of $93.2 million for the six-month period, cash and investments of $373.1 million, and cash runway extending into 2028.","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28599,"accession_number":"0001104659-26-094869","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses ArriVent's financial results for Q2 2026 ended June 30, 2026, with a press release issued on August 12, 2026 furnished as Exhibit 99.1. The press release reports quarterly financial metrics including net loss of $93.2 million for the six-month period, cash and investments of $373.1 million, R\u0026D and G\u0026A expenses, and cash runway into 2028. This is a standard earnings release disclosure for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:16.782715+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28598,"accession_number":"0001104659-26-094869","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"ArriVent entered into an exclusive, sublicensable license agreement with Shanghai Allist Pharmaceuticals on August 11, 2026, granting Allist rights to develop and commercialize ARR-002 in Greater China. The agreement provides for up to $80.6 million in potential payments (upfront, milestones, and royalties), establishes a collaboration committee for joint global development, and represents a material strategic transaction affecting the company's development and commercialization rights for a key asset. This constitutes a material definitive agreement under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:16.782715+00:00","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-08-12"},{"id":28599,"accession_number":"0001104659-26-094869","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses ArriVent's financial results for Q2 2026 ended June 30, 2026, with a press release issued on August 12, 2026 furnished as Exhibit 99.1. The press release reports quarterly financial metrics including net loss of $93.2 million for the six-month period, cash and investments of $373.1 million, R\u0026D and G\u0026A expenses, and cash runway into 2028. This is a standard earnings release disclosure for a clinical-stage biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:11:16.782715+00:00","company_name":"ArriVent BioPharma, Inc.","ticker":"AVBP","filing_date":"2026-08-12"}]}